[go: up one dir, main page]

AR001778A1 - Anticuerpo monoclonal antiintegrinas alfa-v linea de celulas de hibridoma que produce este anticuerpo secuencias de adn que codifican para este anticuerpo composición farmacéutica a base del anticuerpo y un procedimiento para producir dicho anticuerpo - Google Patents

Anticuerpo monoclonal antiintegrinas alfa-v linea de celulas de hibridoma que produce este anticuerpo secuencias de adn que codifican para este anticuerpo composición farmacéutica a base del anticuerpo y un procedimiento para producir dicho anticuerpo

Info

Publication number
AR001778A1
AR001778A1 AR33473095A AR33473095A AR001778A1 AR 001778 A1 AR001778 A1 AR 001778A1 AR 33473095 A AR33473095 A AR 33473095A AR 33473095 A AR33473095 A AR 33473095A AR 001778 A1 AR001778 A1 AR 001778A1
Authority
AR
Argentina
Prior art keywords
antibody
alpha
monoclonal
produces
pharmaceutical composition
Prior art date
Application number
AR33473095A
Other languages
English (en)
Inventor
Francesc Mitjans
Jaume Adan
Jaume Piulats
Simon Goodman
Elisabet Rosell
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR001778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR001778A1 publication Critical patent/AR001778A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

El invento se refiere a un nuevo anticuerpo monoclonal antiintegrinas alfa-V; a una línea de células de hibridoma que produce este anticuerpo; asecuencias de ADN que codifican para este anticuerpo, a secuencias de aminoácidos de esteanticuerpo, a una composición farmacéutica a base delanticuerpo y a un procedimiento para producir dicho anticuerpo. El anticuerpo monoclonal, un ejemplo preferido del cual se denomina 17E6, tiene laspropiedades siguientes: reacciona solamente conla cadena ÓV de las integrinas ÓV humanas; bloquea la unión al sustrato de integrina de la célula portadorade la integrina ÓV; impulsa la reversión de la interacción establecida para la matriz celular, causada por las integrinas ÓV; bloquea eldesa rrollo detumores, y no evidencia acción citotóxica.
AR33473095A 1994-12-20 1995-12-20 Anticuerpo monoclonal antiintegrinas alfa-v linea de celulas de hibridoma que produce este anticuerpo secuencias de adn que codifican para este anticuerpo composición farmacéutica a base del anticuerpo y un procedimiento para producir dicho anticuerpo AR001778A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (1)

Publication Number Publication Date
AR001778A1 true AR001778A1 (es) 1997-12-10

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
AR33473095A AR001778A1 (es) 1994-12-20 1995-12-20 Anticuerpo monoclonal antiintegrinas alfa-v linea de celulas de hibridoma que produce este anticuerpo secuencias de adn que codifican para este anticuerpo composición farmacéutica a base del anticuerpo y un procedimiento para producir dicho anticuerpo

Country Status (26)

Country Link
US (1) US5985278A (es)
EP (1) EP0719859B1 (es)
JP (1) JP3898245B2 (es)
KR (1) KR100450368B1 (es)
CN (1) CN1117763C (es)
AR (1) AR001778A1 (es)
AT (1) ATE244306T1 (es)
AU (1) AU710234B2 (es)
BR (1) BR9505980B1 (es)
CA (1) CA2165573C (es)
CO (1) CO4480042A1 (es)
CZ (1) CZ290477B6 (es)
DE (1) DE69531187T2 (es)
DK (1) DK0719859T3 (es)
ES (1) ES2202336T3 (es)
FI (1) FI118536B (es)
HU (1) HU221061B1 (es)
NO (1) NO321186B1 (es)
PL (1) PL182961B1 (es)
PT (1) PT719859E (es)
RU (1) RU2205223C2 (es)
SI (1) SI0719859T1 (es)
SK (1) SK284932B6 (es)
TR (1) TR199501614A2 (es)
UA (1) UA40621C2 (es)
ZA (1) ZA9510806B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
DE69840113D1 (de) * 1997-08-08 2008-11-20 Univ California Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern
DE69930723T2 (de) * 1998-01-23 2006-11-16 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
EP1372720A4 (en) * 2001-03-02 2006-07-26 Medimmune Inc PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
EP1414491A4 (en) 2001-07-09 2005-07-06 Elan Pharm Inc METHOD OF INHIBITING THE TOXICITY OF AMYLOID
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
JP2005525368A (ja) * 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US20090220504A1 (en) * 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
AU2007272995B2 (en) 2006-07-10 2013-02-07 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2851064A3 (en) 2006-07-11 2015-08-05 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
SI2068889T1 (sl) 2006-08-10 2020-03-31 Roy C. Levitt Anakinra za uporabo pri zdravljenju sindroma bronchiolitisa obliteransa
WO2008141274A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha v immunoliposome composition, methods and uses
WO2008141276A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha-v immunoliposome composition, methods and uses
BRPI0815567B8 (pt) * 2007-07-17 2021-05-25 Merck Patent Gessellschaft Mit Beschraenkter Haftung anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica
HRP20160308T1 (hr) 2007-09-26 2016-04-22 Genentech, Inc. Nova protutijela
ES2440565T3 (es) 2008-12-23 2014-01-29 Merck Patent Gmbh Biomarcadores para inhibidores con actividad anti-angiogénica
JP6051048B2 (ja) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
BR112012011268A2 (pt) 2009-11-13 2019-09-24 Merck Patent Gmbh anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos
SG183356A1 (en) * 2010-02-18 2012-09-27 Univ California INTEGRIN aVß8 NEUTRALIZING ANTIBODY
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
JP6088488B2 (ja) 2011-04-21 2017-03-01 シアトル ジェネティックス， インコーポレイテッド 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
JP6093360B2 (ja) * 2011-08-17 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンα−ｖβ−８と結合する抗体
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10022453B2 (en) 2013-12-23 2018-07-17 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
AU2015317411A1 (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
WO2016041614A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
EP4406606A3 (de) 2015-06-22 2024-10-09 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren g
JP2018528161A (ja) 2015-06-23 2018-09-27 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤との部位特異的均一複合体
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
CN116059390A (zh) 2016-03-24 2023-05-05 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
US20190242908A1 (en) 2016-09-08 2019-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
EP3867276A1 (en) 2018-10-19 2021-08-25 Merck Patent GmbH Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
US20220195052A1 (en) * 2019-04-08 2022-06-23 Biogen Ma Inc. Anti-integrin antibodies and uses thereof
CA3163339A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
US20240158510A1 (en) * 2021-03-09 2024-05-16 The Governing Council Of The University Of Toronto Antibodies against integrin heterodimers and uses thereof
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
ATE244306T1 (de) 2003-07-15
BR9505980A (pt) 1997-12-23
RU2205223C2 (ru) 2003-05-27
CZ328895A3 (en) 1996-09-11
NO955167D0 (no) 1995-12-19
FI118536B (fi) 2007-12-14
CA2165573C (en) 2011-03-29
UA40621C2 (uk) 2001-08-15
SI0719859T1 (en) 2003-12-31
CN1139115A (zh) 1997-01-01
NO321186B1 (no) 2006-04-03
KR100450368B1 (ko) 2005-01-31
JP3898245B2 (ja) 2007-03-28
JPH08231597A (ja) 1996-09-10
ES2202336T3 (es) 2004-04-01
SK159295A3 (en) 1996-07-03
DK0719859T3 (da) 2003-10-20
TR199501614A2 (tr) 1996-07-21
PL182961B1 (pl) 2002-05-31
EP0719859B1 (en) 2003-07-02
PL311926A1 (en) 1996-06-24
CA2165573A1 (en) 1996-06-21
HUT74828A (en) 1997-02-28
FI956112A0 (fi) 1995-12-19
HU221061B1 (hu) 2002-07-29
KR960022562A (ko) 1996-07-18
DE69531187D1 (de) 2003-08-07
CN1117763C (zh) 2003-08-13
PT719859E (pt) 2003-11-28
SK284932B6 (sk) 2006-02-02
US5985278A (en) 1999-11-16
CZ290477B6 (cs) 2002-07-17
FI956112L (fi) 1996-06-21
HU9503638D0 (en) 1996-02-28
EP0719859A1 (en) 1996-07-03
CO4480042A1 (es) 1997-07-09
DE69531187T2 (de) 2004-04-22
AU710234B2 (en) 1999-09-16
BR9505980B1 (pt) 2010-02-23
ZA9510806B (en) 1996-05-30
AU4042195A (en) 1996-06-27
NO955167L (no) 1996-06-21

Similar Documents

Publication Publication Date Title
AR001778A1 (es) Anticuerpo monoclonal antiintegrinas alfa-v linea de celulas de hibridoma que produce este anticuerpo secuencias de adn que codifican para este anticuerpo composición farmacéutica a base del anticuerpo y un procedimiento para producir dicho anticuerpo
HRP20050986A2 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
DE69412614D1 (de) Recombinante disulfid-stabilisierte polypeptide mit bindung spezifität
CL2009000575A1 (es) Anticuerpos aislados anti-interleuquina 12 (anti il-12) de mamiferos, secuencia de nucleotidos, vector, celula y metodo de produccion, composicion y dispositivo medico que contienen, util en el diagnostico y tratamiento de condicones relacionadas con il-12.
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
NZ595450A (en) Antibodies to M-CSF
RU2012102323A (ru) Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента
ATE402717T1 (de) Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
CO5550468A2 (es) Inmunoconjugados del anticuerpo cd44 citotoxico
DK368588D0 (da) Bindingsmolekyler med en enkelt plypeptidkaede
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
EP1077719A4 (en) VACCINE DELIVERY SYSTEM
ATE472556T1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ES2567402T3 (es) Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
ATE414150T1 (de) Einzelkettiges, mehrfach-antigenbindendes molekül,dessen herstellung und verwendung
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
UY30524A1 (es) Anticuerpos dirigidos a avb(beta)6 y sus usos
DK0765343T3 (da) Monoklonale antistoffer imod CD44v6
DE69329195D1 (de) Rekombinante dna moleküle die aminopeptidase enzyme kodieren und ihre anwendung für die herstellung von impfstoffen gegen helminth infektionen
ATE148168T1 (de) Monoklonale antikörper
AR036154A1 (es) Anticuerpos especificos de cd44v6.
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
CO4520255A1 (es) Terapia de tumores mediante linfocitos t citotoxicos de transferencia adoptivos especificos de cd44v

Legal Events

Date Code Title Description
FG Grant, registration